[Skip to Content]
[Skip to Content Landing]
Views 1,082
Citations 0
Comment & Response
March 8, 2016

Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

Author Affiliations
  • 1Harvard Radiation Oncology Program, Boston, Massachusetts
  • 2Genitourinary Malignancies Program, Massachusetts General Hospital, Boston
  • 3Department of Radiation Oncology, Massachusetts General Hospital, Boston

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;315(10):1054-1055. doi:10.1001/jama.2015.17567

To the Editor In an update of their randomized clinical trial, Dr D’Amico and colleagues1 reported that combined radiation therapy (RT) and androgen deprivation therapy (ADT) was no longer associated with an overall survival benefit among 206 men with unfavorable localized prostate cancer after a median of 16.6 years.

These observations are inconsistent with 2 prior reports of this trial and with the results of multiple randomized trials (involving >8000 men) that have consistently demonstrated a survival benefit with the addition of ADT for men receiving RT with intermediate, high-risk, and locally advanced prostate cancer.2

First Page Preview View Large
First page PDF preview
First page PDF preview